Swedish Orphan Biovitrum

BNP Paribas boosts SOBI target to 555 kronor, citing strong growth potential in rare‑disease biotech and robust financials. Discover why investors are bullish on Swedish Orphan Biovitrum.

FDA’s CRL for SOBI’s NASP therapy highlights CMC and manufacturing fixes needed, but confirms safety and efficacy, boosting investor confidence and market outlook.